Venock Inc. Paves the Way for First Universal Large Bore Vascular Closure System Designed for Veins and Arteries

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NEW YORK & MUNICH–(BUSINESS WIRE)–#arterialclosure–Privately held medical technology company Venock, Inc., headquartered in New York City, with the subsidiary Venock Medical GmbH in Munich, Germany, announced that it has expanded the design of its large bore venous closure system to also be effective at high pressure conditions for closure of large bore arterial perforations.

Venock is developing a vascular closure system for large bore punctures in vessels following transvenous catheter-based therapies like atrial ablations, leadless pacemaker implantations and various structural heart therapies such as Mitral- and Tricuspid- Valve repair and replacement. Additionally, the Venock device will close large bore arterial access sites left by, percutaneous aortic valve implantations (TAVI), catheter based ventricular assist devices and pulmonary assist systems (ECMO). All such therapies are facing growing demand and require large bore vascular access, with sites that can be as big as the diameter of the vessel itself.

“We invested a great deal of effort to expand our large bore venous closure technology to include closure of large bore arterial perforations. Venock is developing the first universal large bore closure device for veins and arteries. We will plan our first IDE clinical study to enroll 120 patients with large bore venous interventional procedures in 10 clinical centers with a 30 day follow up,” explains Terry Barnes, CEO of Venock.

About Venock Inc.

Venock Inc. is a privately held US medical device company headquartered in New York City, with the subsidiary Venock Medical GmbH in Munich, Germany. Its Vascular Closure Device is designed to close very large perforations that can be as big as the diameter of the vein or the artery.

CAUTION: The Venock system is not approved for sale or investigational use.

DISCLAIMER:

All information contained in this document derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this document or its contents. This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. International investors acknowledge risks in connection with political and economic uncertainties in foreign countries as well as currency risks. Persons who are in possession of this document are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends, or circumstances after the date of this press release.

Contacts

Terry Barnes, CEO

terry.barnes@venock.com
Mobile: +49 170 557 0073

Venock Inc.: www.venock.com

Staff

Recent Posts

Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare

SAN FRANCISCO, Aug. 14, 2025 /PRNewswire/ -- Citizen Health, a patient-powered platform transforming rare disease…

3 hours ago

Enterprise Imaging IT Market worth US$4.12 Billion by 2030 with 12.2% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 14, 2025 /PRNewswire/ -- The global Enterprise Imaging IT Market, valued at…

3 hours ago

With 722% Revenue Growth Over Three Years, Alafair Biosciences Celebrates Its Third Appearance on the Inc. 5000 List

Alafair Rises in Inc. 5000 Rankings as Growth Accelerates Ahead of VersaCoat™ Flowable Hydrogel Launch AUSTIN, Texas,…

3 hours ago

Philadelphia Phillies Expand Groundbreaking Partnership with NexGen Hyperbaric into Multi-Year Agreement, Becoming the First MLB Team to Invest in Mobile HBOT

Innovative medical-grade oxygen therapy aids in player recovery and return from injury PHILADELPHIA, Aug. 14,…

3 hours ago

Nexsys Acquires Palomar Billing Services, Expanding Technology -Driven Revenue Cycle Capabilities for Independent Physician Practices Nationwide

TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Nexsys Billing & Practice Management, a leading provider…

3 hours ago

Vital User Count Surges Past 5-Million Patients, Expected to Triple by 2026

CLAYMONT, Del., Aug. 14, 2025 /PRNewswire/ -- Vital, an AI-powered patient experience platform, today announced…

3 hours ago